AAV2-VEGFi

AAV2-VEGFi is an adeno-associated virus serotype 2 (AAV2) gene therapy vector designed for the localized treatment of solid tumors. It carries a transgene encoding a synthetic VEGF inhibitor (VEGFi) composed of VEGFR1 and VEGFR2-derived decoy domains. Expression of the inhibitor is controlled by a hypoxia-responsive CMV/HRE promoter, ensuring that the anti-angiogenic activity is concentrated within the hypoxic environment of the tumor. By sequestering Vascular Endothelial Growth Factor (VEGF), the therapy aims to suppress primary tumor growth and inhibit metastatic dissemination. Research conducted at the Tehran University of Medical Sciences has demonstrated its efficacy in suppressing tumor growth and reducing metastatic burden in immunocompetent breast cancer models.